Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
HLA-A (MHC I) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone 108-2C5 ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IF, FC |
|---|---|
| Primary Accession | P01889 |
| Other Accession | 3105, 181244, 654404, 77961, P30443, P30499 |
| Reactivity | Human |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | Mouse / IgG1, kappa |
| Clone Names | 108-2C5 |
| Calculated MW | ~41kDa |
| Gene ID | 3106 |
|---|---|
| Other Names | HLA class I histocompatibility antigen, B-7 alpha chain, MHC class I antigen B*7, HLA-B, HLAB |
| Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
| Precautions | HLA-A (MHC I) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | HLA-B (HGNC:4932) |
|---|---|
| Synonyms | HLAB |
| Function | Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:23209413, PubMed:25808313, PubMed:29531227, PubMed:9620674). May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity (PubMed:18991276, PubMed:7743181). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (PubMed:24600035, PubMed:29531227, PubMed:9620674). Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via constitutive proteasome and IFNG-induced immunoproteasome (PubMed:23209413). Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9 (PubMed:25808313, PubMed:29531227). |
| Cellular Location | Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
HLA-A, with HLA-B and HLA-C, belongs to major histocompatibility complex (MHC) class I antigens and expresses constitutively on all nucleated cells. MHC class I antigens play a role in class I MHC-associated antigen presentation, inhibition of NK cell cytotoxicity, tumor surveillance, and tissue allotransplantation. This MAb is useful for HLA molecular typing of peripheral blood leukocytes as well as a large number of leukemic cell lines. It reacts with an intralocus determinant present on a limited number of HLA-A locus-encoded gene products (HLA-A2, -A3, -A28, -A29, -A30, -A31 and �Aw33). Its epitope maps between aa65-to-aa80 of the ?1 domain of the HLA-A. This MAb recognizes an intralocus determinant present on a limited number of HLA-A locus-encoded gene products (HLA-A2, -A3, A28, -A29, -A30, -A31 and -Aw33). Furthermore, by testing its reactivity with HLA-A2 natural variants and mutants, the importance of amino acid residues 79 and/or 80 of the α1 domain was demonstrated in the formation of an intralocus HLA-A determinant.
References
Domenech N et al. Hum Immunol 1991, 30(2):140-6 | Lozano F et al. Immunogenetics 1989, 30::50-3 | Lozano F et al. Tissue Antigens 1990, 35:193-5 | Young NT et al. Hum Immunol 1997, 52(1):1-11 | Krensky AM et al Transplant Proc 1996, 28(6):3026-8 | Hansen JA et al Hematol Oncol Clin North Am 1990, 4(3):507-515
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
